Wednesday, March 19, 2008

Predictive Biosciences names Klemm as its first president and CEO

Predictive Biosciences Inc. has named Peter Klemm as the company's first president and chief executive officer, according to company officials.

Klemm, formerly CEO of molecular diagnostics company GeneOhm Sciences, will also be named a director of the company, effective Monday, March 24. Klemm's appointment comes on the heels of the recent announcement that Martin Madaus, president, CEO and chairman of Millipore Corp., joined the board of directors of Predictive Biosciences.

Predictive Biosciences makes urine-based tests using patented and proprietary protein biomarkers and clinical algorithms to allow physicians to determine the presence or absence of cancer.

Klemm ran GeneOhm Sciences, which he built from its inception in 2002 until it was sold to Becton Dickinson in 2006 for $230 million. Prior to GeneOhm Sciences, Klemm was CEO of JOMED Inc., a Swiss company that develops and manufactures products for interventional cardiology, radiology and minimally invasive vascular surgery.

Predictive Biosciences was launched in 2006 and is privately funded by Highland Capital Partners and Flybridge Capital Partners (formerly IDG Ventures Atlantic).